Bridgefront Capital LLC acquired a new position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) during the third quarter, Holdings Channel reports. The firm acquired 15,396 shares of the biotechnology company’s stock, valued at approximately $160,000.
A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Quadrant Capital Group LLC raised its position in shares of Ironwood Pharmaceuticals by 2,065.5% during the third quarter. Quadrant Capital Group LLC now owns 3,768 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 3,594 shares during the period. Lazard Asset Management LLC acquired a new stake in shares of Ironwood Pharmaceuticals during the first quarter worth $78,000. Captrust Financial Advisors raised its position in shares of Ironwood Pharmaceuticals by 441.7% during the second quarter. Captrust Financial Advisors now owns 6,690 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 5,455 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Ironwood Pharmaceuticals during the first quarter worth $109,000. Finally, Virtu Financial LLC acquired a new position in Ironwood Pharmaceuticals during the second quarter valued at $123,000.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on Ironwood Pharmaceuticals in a research report on Thursday. They set a “buy” rating on the stock.
Insider Buying and Selling at Ironwood Pharmaceuticals
Ironwood Pharmaceuticals Trading Down 1.0 %
NASDAQ:IRWD opened at $10.37 on Friday. The business’s fifty day moving average price is $11.26 and its 200 day moving average price is $11.25. Ironwood Pharmaceuticals, Inc. has a 1-year low of $9.73 and a 1-year high of $12.95. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of 10.69 and a beta of 0.94.
Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Rating) last issued its earnings results on Thursday, February 16th. The biotechnology company reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). Ironwood Pharmaceuticals had a net margin of 42.64% and a return on equity of 30.49%. The firm had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $108.23 million. During the same quarter last year, the firm earned $0.27 EPS. The business’s revenue for the quarter was down 8.5% compared to the same quarter last year. Equities analysts forecast that Ironwood Pharmaceuticals, Inc. will post 1.05 earnings per share for the current year.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.
- Get a free copy of the StockNews.com research report on Ironwood Pharmaceuticals (IRWD)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating).
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.